Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model

Kidney International

Volumn 78, Issue 11, 2010, Pages 1136-1153

  Leelahavanichkul, Asada ^a,b   Yan, Qin ^a   Hu, Xuzhen ^a   Eisner, Christoph ^a   Huang, Yuning ^a   Chen, Richard ^a   Mizel, Diane ^a   Zhou, Hua ^a   Wright, Elizabeth C ^a   Kopp, Jeffrey B ^a   Schnermann, Jürgen ^a   Yuen, Peter S T ^a   Star, Robert A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

angiotensin II; blood pressure; glomerulosclerosis; interstitial fibrosis; telemetry

Indexed keywords

ANGIOTENSIN II;

ALBUMINURIA; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; GLOMERULOSCLEROSIS; HEART MUSCLE FIBROSIS; HYPERTENSION; KIDNEY FIBROSIS; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 78349306509     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.287     Document Type: Article

References (80)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
2. Patel SS, Kimmel PL, Singh A. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol 2002; 22: 449-458.
3. Hossain MP, Goyder EC, Rigby JE et al. CKD and poverty: a growing global challenge. Am J Kidney Dis 2009; 53: 166-174.
4. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
5. Mitka M. Report notes increase in kidney disease. JAMA 2008; 300: 2473-2474.
6. Brosius III FC, Alpers CE, Bottinger EP et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2503-2512.
7. Schnaper HW, Kopp JB. Renal fibrosis. Front Biosci 2003; 8: e68-e86.
8. Fogo AB. Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol 2003; 23: 161-171.
9. Hayslett JP. Functional adaptation to reduction in renal mass. Physiol Rev 1979; 59: 137-164.
10. Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 1975; 79: 95-106.
11. Novick AC, Gephardt G, Guz B et al. Long-term follow-up after partial removal of a solitary kidney. N Engl J Med 1991; 325: 1058-1062.
12. Hodgin JB, Rasoulpour M, Markowitz GS et al. Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009; 4: 71-76.
13. Lackland DT, Bendall HE, Osmond C et al. Low birth weights contribute to high rates of early-onset chronic renal failure in the Southeastern United States. Arch Intern Med 2000; 160: 1472-1476.
14. Vikse BE, Irgens LM, Leivestad T et al. Low birth weight increases risk for end-stage renal disease. J Am Soc Nephrol 2008; 19: 151-157.
15. Aigner B, Rathkolb B, Herbach N et al. Screening for increased plasma urea levels in a large-scale ENU mouse mutagenesis project reveals kidney disease models. Am J Physiol Renal Physiol 2007; 292: F1560-F1567.
16. Cvetkovic B, Sigmund CD. Understanding hypertension through genetic manipulation in mice. Kidney Int 2000; 57: 863-874.
17. Kohan DE. Progress in gene targeting: using mutant mice to study renal function and disease. Kidney Int 2008; 74: 427-437.
18. Tchekneva EE, Rinchik EM, Polosukhina D et al. A sensitized screen of N-ethyl-N-nitrosourea-mutagenized mice identifies dominant mutants predisposed to diabetic nephropathy. J Am Soc Nephrol 2007; 18: 103-112.
19. Doi K, Leelahavanichkul A, Hu X et al. Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int 2008; 74: 1017-1025.
20. Klingler Jr EL, Evan AP, Anderson RE. Folic acid-induced renal injury and repair. Correlation of structural and functional abnormalities. Arch Pathol Lab Med 1980; 104: 87-93.
21. Al Banchaabouchi M, Marescau B, D'Hooge R et al. Biochemical and histopathological changes in nephrectomized mice. Metabolism 1998; 47: 355-361.
22. Ma LJ, Fogo AB. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 2003; 64: 350-355.
23. Kren S, Hostetter TH. The course of the remnant kidney model in mice. Kidney Int 1999; 56: 333-337.
24. Kennedy DJ, Elkareh J, Shidyak A et al. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol 2008; 294: F450-F454.
25. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009; 75: 800-808.
26. Waldherr R, Gretz N. Natural course of the development of histological lesions after 5/6 nephrectomy. Contrib Nephrol 1988; 60: 64-72.
27. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
28. Whitesall SE, Hoff JB, Vollmer AP et al. Comparison of simultaneous measurement of mouse systolic arterial blood pressure by radiotelemetry and tail-cuff methods. Am J Physiol Heart Circ Physiol 2004; 286: H2408-H2415.
29. Bazil MK, Krulan C, Webb RL. Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 22: 897-905.
30. Festing MF, Simpson EM, Davisson MT et al. Revised nomenclature for strain 129 mice. Mamm Genome 1999; 10: 836.
31. Crowley SD, Gurley SB, Herrera MJ et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006; 103: 17985-17990.
32. Francois H, Athirakul K, Mao L et al. Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension 2004; 43: 364-369.
33. Diz DI, Baer PG, Nasjletti A. Angiotensin II-induced hypertension in the rat. Effects on the plasma concentration, renal excretion, and tissue release of prostaglandins. J Clin Invest 1983; 72: 466-477.
34. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
35. Ma LJ, Yang H, Gaspert M et al. Transforming growth factor-p-dependent and -independent pathways of induction of tubulointerstitial fibrosis in p6 (-/-) mice. Am J Pathol 2003; 163: 1261-1273.
36. Bellizzi V, Sabbatini M, Fuiano G et al. The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model. Nephrol Dial Transplant 1998; 13: 2210-2215.
37. Priyadarshi A, Periyasamy S, Burke TJ et al. Effects of reduction of renal mass on renal oxygen tension and erythropoietin production in the rat. Kidney Int 2002; 61: 542-546.
38. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 1994; 4: 2023-2031.
39. Gabizon D, Goren E, Shaked U et al. Induction of chronic renal failure in the mouse: a new model. Nephron 1985; 40: 349-352.
40. Gagnon RF, Ansari M. Development and progression of uremic changes in the mouse with surgically induced renal failure. Nephron 1990; 54: 70-76.
41. Gagnon RF, Duguid WP. A reproducible model for chronic renal failure in the mouse. Urol Res 1983; 11: 11-14.
42. Hait MR, Robb CA, Baxter CR et al. Comparative evaluation of Avitene microcrystalline collagen hemostat in experimental animal wounds. Am J Surg 1973; 125: 284-287.
43. Ainscough JF, Drinkhill MJ, Sedo A et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 2009; 81: 592-600.
44. Billet S, Aguilar F, Baudry C et al. Role of angiotensin II AT1 receptor activation in cardiovascular diseases. Kidney Int 2008; 74: 1379-1384.
45. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 2002; 34: 1577-1584.
46. Matsusaka T, Katori H, Homma T et al. Mechanism of cardiac fibrosis by angiotensin. New insight revealed by genetic engineering. Trends Cardiovasc Med 1999; 9: 180-184.
47. Yamazaki T, Komuro I, Yazaki Y. Role of the renin-angiotensin system in cardiac hypertrophy. Am J Cardiol 1999; 83: 53H-57H.
48. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363-366.
49. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340.
50. Wright Jr JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
51. Wuhl E, Trivelli A, Picca S et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361: 1639-1650.
52. Mattson DL. Comparison of arterial blood pressure in different strains of mice. Am J Hypertens 2001; 14: 405-408.
53. Bidani AK, Griffin KA, Picken M et al. Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am J Physiol 1993; 265: F391-F398.
54. Kurtz TW, Griffin KA, Bidani AK et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 2: Blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension 2005; 45: 299-310.
55. Bunag RD, McCubbin JW, Page IH. Lack of correlation between direct and indirect measurements of arterial pressure in unanaesthetized rats. Cardiovasc Res 1971; 5: 24-31.
56. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet 1988; 2: 397.
57. Remuzzi G, Perico N, Macia M et al. The role of renin-angiotensin- aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005: S57-S65.
58. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
59. Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
60. Ketteler M, Noble NA, Border WA. Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 1995; 57: 279-295.
61. Wolf G. Angiotensin II as a renal growth factor. Contrib Nephrol 2001; 135: 92-110.
62. Swirski FK, Nahrendorf M, Etzrodt M et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325: 612-616.
63. Sinnayah P, Lindley TE, Staber PD et al. Targeted viral delivery of Cre recombinase induces conditional gene deletion in cardiovascular circuits of the mouse brain. Physiol Genomics 2004; 18: 25-32.
64. Kobori H, Nangaku M, Navar LG et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287.
65. Freedman BI, Hicks PJ, Bostrom MA et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009; 75: 736-745.
66. Freedman BI, Kopp JB, Winkler CA et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN Study. Am J Nephrol 2009; 29: 626-632.
67. Kao WH, Klag MJ, Meoni LA et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185-1192.
68. Kopp JB, Smith MW, Nelson GW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184.
69. Megyesi J, Price PM, Tamayo E et al. The lack of a functional p21 (WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA 1999; 96: 10830-10835.
70. Basile DP, Donohoe D, Roethe K et al. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 2001; 281: F887-F899.
71. Basile DP, Fredrich K, Alausa M et al. Identification of persistently altered gene expression in the kidney after functional recovery from ischemic acute renal failure. Am J Physiol Renal Physiol 2005; 288: F953-F963.
72. Seok YM, Kim J, Park MJ et al. Wen-pi-tang-Hab-Wu-ling-san attenuates kidney fibrosis induced by ischemia/reperfusion in mice. Phytother Res 2008; 22: 1057-1063.
73. Srisawat N, Manotham K, Eiam-Ong S et al. Erythropoietin and its non-erythropoietic derivative: do they ameliorate renal tubulointerstitial injury in ureteral obstruction? Int J Urol 2008; 15: 1011-1017.
74. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
75. Yoshida K, Kohzuki M. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist. Cardiovasc Drug Rev 2004; 22: 285-308.
76. Karatas A, Hegner B, de Windt LJ et al. Deoxycorticosterone acetate-salt mice exhibit blood pressure-independent sexual dimorphism. Hypertension 2008; 51: 1177-1183.
77. Yuen PS, Dunn SR, Miyaji T et al. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004; 286: F1116-F1119.
78. Doi K, Yuen PS, Eisner C et al. Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol 2009; 20: 1217-1221.
79. MacKay K, Striker LJ, Pinkert CA et al. Glomerulosclerosis and renal cysts in mice transgenic for the early region of SV40. Kidney Int 1987; 32: 827-837.
80. Johnson JT, Hansen MS, Wu I et al. Virtual histology of transgenic mouse embryos for high-throughput phenotyping. PLoS Genet 2006; 2: e61.